Allergan, Inamed unite
This article was originally published in The Gray Sheet
Executive Summary
After a series of delays, Allergan finally nabs more than 90% of outstanding Inamed shares to complete its acquisition of the aesthetics firm. On March 23, Allergan announced that thanks to one final extension, Inamed shareholders had tendered nearly 94% of outstanding stock by the March 17 deadline, allowing the $3.2 bil. deal to proceed under Delaware's short-form merger statute. Though nearly all Inamed shareholders elected to receive Allergan stock, under the terms of the deal Allergan will instead give the shareholders 0.46 shares of Allergan and $37.71 for each share of Inamed...